What is iovera°?
iovera° operates at the intersection of medical device innovation and pain management, providing a sophisticated, FDA-cleared system that utilizes extreme cold to block pain signals from peripheral nerves. By targeting conditions such as osteoarthritis and post-surgical recovery, the company has established a unique market position as a leader in non-pharmacological intervention. The technology is designed to provide relief for up to 90 days, offering a compelling value proposition for patients seeking to avoid the systemic side effects associated with traditional opioid-based treatments. As a high-growth medical technology firm, iovera° continues to refine its clinical applications across the hip, shoulder, and spine, effectively disrupting the standard of care in orthopedic and pain management clinics.
How much funding has iovera° raised?
iovera° has raised a total of $72.6M across 6 funding rounds:
Debt
$2.2M
Private Equity
$18.8M
Private Equity
$32.7M
Private Equity
$10M
Debt
$8.4M
Unspecified
$556K
Debt (2010): $2.2M, investors not publicly disclosed
Private Equity (2011): $18.8M, investors not publicly disclosed
Private Equity (2012): $32.7M supported by Medicis Capital, Accuitive Medical Ventures, DeNovo Ventures, and Saratoga Ventures, L.P.
Private Equity (2013): $10M featuring Valiance Asset Management Limited, DeNovo Ventures, Medicis Capital Group, and Accuitive Medical Ventures
Debt (2014): $8.4M backed by NMT Capital
Unspecified (2017): $556K, investors not publicly disclosed
Key Investors in iovera°
Medicis Capital
A specialized healthcare investment firm providing strategic and operational expertise to midsized companies in the Pharma, Biotech, and MedTech sectors across Western Europe.
Accuitive Medical Ventures
A market-driven venture capital firm focused on revolutionary medical device technologies, often collaborating with The Innovation Factory to build long-term shareholder value.
Valiance Asset Management Limited
A global investment firm that partners with impactful technology businesses, prioritizing social impact and life-changing outcomes alongside financial returns.
What's next for iovera°?
With the support of its institutional partners, iovera° is well-positioned to accelerate its commercialization strategy and deepen its penetration into the global pain management market. The recent infusion of capital is expected to drive further clinical validation and support the scaling of its operational infrastructure. Future strategic initiatives will likely focus on expanding the reach of its cryoneurolysis platform, potentially exploring new therapeutic indications and strengthening its competitive moat against traditional pharmaceutical pain management solutions. By leveraging its established network of healthcare providers and its proven track record of clinical efficacy, iovera° is poised to maintain its leadership in the non-opioid therapeutic space, ensuring long-term value creation for its stakeholders and improved outcomes for patients suffering from chronic pain.
See full iovera° company page
